Combination of dasatinib plus Nivolumab  - CML

Important notice: You must inform your CML doctor or a qualified doctor before using this drug. The material presented here is for information purposes only;  it is not a substitute for your physician’s guidance and care.

CLINICAL TRIALS

A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia

 
ARTICLES

Nivolumab to control molecular response in chronic myeloid leukemia
September 2018, Leukemia Research

CA180-373 = A Phase 1B Study with Dasatinib plus Nivolumab in CML
November 1,  2017, CML Advocates Network

An open-label, phase 1b, dose-escalation study (CA180-373) of dasatinib plus nivolumab, an investigational anti-programmed cell death 1 (PD-1) antibody, in patients (pts) with previously treated chronic myeloid leukemia (CML).
2014, Journal Of Clinical Oncology

                                        Return to Cure possible for  CML?